Differences

This shows you the differences between two versions of the page.

--- endocrine:glp1:semaglutide [2026/02/13 00:15] – [Obesity ★] andrew2393cns
+++ endocrine:glp1:semaglutide [2026/02/13 00:17] (current) – [Clinical Pearls] andrew2393cns
@@ Line 55: / Line 55: @@
 Semaglutide reduces:
-• Myocardial infarction
+  * • Myocardial infarction
-• Stroke
+  * • Stroke
-• Cardiovascular death
+  * • Cardiovascular death
 Particularly beneficial in patients with established ASCVD.
@@ Line 84: / Line 84: @@
 Injectable (weekly):
-• Ozempic
+  * • Ozempic
-• Wegovy (higher obesity dose)
+  * • Wegovy (higher obesity dose)
 Oral (daily):
-• Rybelsus
+  * • Rybelsus
 Oral formulation requires:
-• Empty stomach
+  * • Empty stomach
-• Limited water
+  * • Limited water
-• No food for 30 minutes
+  * • No food for 30 minutes
 --------------------------------------------------------------------
@@ Line 101: / Line 101: @@
 Common:
-• Nausea
+  * • Nausea
-• Vomiting
+  * • Vomiting
-• Diarrhea
+  * • Diarrhea
-• Early satiety
+  * • Early satiety
 Serious (rare):
-• Pancreatitis
+  * • Pancreatitis
-• Gallbladder disease
+  * • Gallbladder disease
-• Theoretical risk of medullary thyroid carcinoma
+  * • Theoretical risk of medullary thyroid carcinoma
 Weight loss may increase gallstone risk.
@@ Line 118: / Line 118: @@
 ===== Contraindications =====
-• Personal or family history of medullary thyroid carcinoma
+  * • Personal or family history of medullary thyroid carcinoma
-• MEN2 syndrome
+  * • MEN2 syndrome
-• Severe GI disease
+  * • Severe GI disease
 Use caution in:
-• History of pancreatitis
+  * • History of pancreatitis
 --------------------------------------------------------------------
@@ Line 131: / Line 131: @@
 [[endocrine:glp1:exenatide|Exenatide]]:
-• Shorter acting
+  * • Shorter acting
-• Less weight loss
+  * • Less weight loss
 [[endocrine:glp1:liraglutide|Liraglutide]]:
-• Daily injection
+  * • Daily injection
-• Proven ASCVD benefit
+  * • Proven ASCVD benefit
 [[endocrine:glp1:dulaglutide|Dulaglutide]]:
-• Weekly injection
+  * • Weekly injection
-• Strong ASCVD benefit
+  * • Strong ASCVD benefit
 Semaglutide:
-• Strongest weight loss among GLP-1 RAs
+  * • Strongest weight loss among GLP-1 RAs
-• Strong ASCVD reduction
+  * • Strong ASCVD reduction
-• Available oral formulation
+  * • Available oral formulation
 --------------------------------------------------------------------
@@ Line 153: / Line 153: @@
 Semaglutide:
-• Strong ASCVD reduction
+  * • Strong ASCVD reduction
-• Weight loss dominant
+  * • Weight loss dominant
 [[endocrine:sglt2:start|SGLT2 Inhibitors]]:
-• Strong heart failure benefit
+  * • Strong heart failure benefit
-• Strong renal protection
+  * • Strong renal protection
 These classes are often combined in cardiometabolic patients.
@@ Line 167: / Line 167: @@
 ===== Clinical Pearls =====
-✔ Weekly or oral option
+  * ✔ Weekly or oral option
-✔ Powerful weight loss
+  * ✔ Powerful weight loss
-✔ Reduces ASCVD events
+  * ✔ Reduces ASCVD events
-✔ Low hypoglycemia risk
+  * ✔ Low hypoglycemia risk
-✔ Not a core heart failure therapy
+  * ✔ Not a core heart failure therapy
-✔ Monitor for GI intolerance
+  * ✔ Monitor for GI intolerance
 --------------------------------------------------------------------